A cross-sectional study found that human papillomavirus (HPV) had a higher probability of being diagnosed in women born in the 1980s compared with women born in the 1990s.
The vaccine for human papillomavirus (HPV) was recommended for routine use starting in 2006 for young women aged 9 to 26 years old. To assess the effectiveness of the vaccine, a study published in JAMA Health Forum compared the probability of women born in the 1980s and 1990s being diagnosed with HPV. The researchers found that women born in the 1990s were at a lower risk of HPV.
Data from 2 cycles of the National Health and Nutritional Examination Survey (2005-2006 and 2015-2016) were used for this study. Infection prevalence of HPV types 16 and 18 were estimated. Data analyses were performed.
There were 2698 women aged 18 to 26 years (mean [SD] age of 21.5 [2.7] years) and 32% White. Prevalence of HPV-16/18 was significantly lower in women born in the 1990s (5.6%; 95% CI, 4.0%-7.2%) compared with the women born in the 1980s (12.5%; 95% CI, 10.2%-14.7%).
At least half of each smaller age group had received 1 or more doses of the HPV vaccine in the 2015-2016 cycle (55% in those aged 18 to 20 years; 52% in those aged 21 to 23 years; and 50% of those aged 24 to 26). Prevalence of HPV decreased from the cycle before vaccination introduction in 2005-2006 (15.2%; 95% CI, 11.2%-19.1%) to 2015-2016 (3.3%; 95% CI, 1.3%-5.3%). Unvaccinated individuals had a 5.1% prevalence (95% CI, 1.2%-9.1%) and vaccinated individuals had a 1.0% (95% CI, 0.0%-2.5%) prevalence.
Women born in the 1990s had a 54% lower estimated probability of HPV-16/18 (6.3%; 95% CI, 5.7%-6.9%) compared with those born in the 1980s (13.6%; 95% CI, 12.7%-14.4%). The 2015-2016 cycle saw a 78% lower probability (3.5%; 95% CI, 2.9%-4.1%) compared with the 2005-2006 (15.7%; 95% CI, 14.0%-17.4%); the probability was 60% lower in unvaccinated women (6.3%; 95% CI, 5.0%-7.4%) and 92% lower for vaccinated women (1.2%; 95% CI, 1.0%-1.3%).
This study was limited by the self-reported reports of HPV vaccination status and also the exclusion of other types of HPV that were not covered by the vaccine.
The researchers concluded that HPV infection in women was lower in those born in the 1990s and in the post-vaccination period (2015-2016) across all demographics when compared with those born in the 1980s and women from the prevaccination cycle (2005-2006).
Reference
Shahmoradi Z, Damgacioglu H, Montealegre J, et al. Prevalence of human papillomavirus infection among women born in the 1990s vs the 1980s and association with HPV vaccination in the US. JAMA Health Forum. 2022;3(8):e222706. doi:10.1001/jamahealthforum.2022.2706
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
Variable Long COVID Definitions Create Hurdles in Care, Research
August 12th 2025There is a need to consolidate various long COVID definitions to establish a standardized definition that ensures consistent recognition, documentation, diagnosis, and treatment, according to new research.
Read More
Bird Flu Risks, Myths, and Prevention Strategies: A Conversation With the NFID's Dr Robert Hopkins
January 21st 2025Joining us for this episode of Managed Care Cast is Robert H. Hopkins Jr, MD, medical director at the National Foundation for Infectious Diseases (NFID), who will help separate fact from fiction about avian influenza and discuss what needs to be done to prevent a future escalation.
Listen
Prenatal PFAS Exposure Alters Infant Vaccine-Related Immune Cells
August 1st 2025Prenatal exposure to per- and polyfluoroalkyl substances (PFAS), a class of persistent environmental pollutants, was linked to significant shifts in infant T helper cell development, raising concerns about long-term effects on vaccine response, immune regulation, and disease susceptibility.
Read More
Updated mRNA Vaccines Against JN.1 Show Strong Safety Signal in Real-World Data
July 31st 2025A nationwide Danish cohort study demonstrated no increased risk of serious adverse events following vaccination with JN.1-updated mRNA COVID-19 vaccines, reinforcing their safety profile and supporting continued use in high-risk populations amid ongoing viral evolution.
Read More